Summit Therapeutics
Summit Therapeutics Logo
Logos are displayed for identification only. Logokit is not affiliated with, endorsed by, or sponsored by the companies shown.
About Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical company developing and commercializing therapies for serious unmet medical needs. Its lead program is ivonescimab (SMT112), a bispecific antibody designed to block PD-1 and angiogenesis pathways. The company is developing ivonescimab through a collaboration and license agreement with Akeso and is conducting clinical programs in lung and colorectal cancer.
Address
601 Brickell Key Drive, Suite 1000
Miami, 33131
United States
Year founded
2020
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Add Summit Therapeutics logo and brand data to your app or website
Embed this logo using a simple HTML tag, or access structured brand data with a single call to our API.
<img src="https://img.logokit.com/summittxinc.com" />
Report inaccurate data
Request an update to help us keep the brand up-to-date.
